



BioSpect

the business of BI

24 years of leveraging the business of Bio
www.biospectrumindia.com

Agilus Diagnostics launches Idylla System for rapid detection of cancer mutations

09 June 2026 | News

Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology



Agilus Diagnostics, subsidiary of Fortis Healthcare, has launched the automated **Idylla molecular diagnostics system** at its Goregaon laboratory in Mumbai, enabling rapid detection of cancer-related genetic mutations within **2.5 to 3 hours**.

The launch marks a significant advancement in accelerating clinical decision-making and expanding access to precision oncology in India.

The Idylla system is a fully integrated, cartridge-based molecular testing platform that combines **sample processing, nucleic acid extraction, amplification and detection** into a single automated workflow. By minimising manual intervention and pre-analytical variability, the system delivers highly accurate and reproducible results in a significantly shorter timeframe compared to conventional molecular testing methods, which can take several days.

This capability is particularly critical in oncology, where timely identification of actionable biomarkers plays a decisive role in guiding targeted therapies. The platform enables rapid detection of clinically relevant mutations, including:

- **EGFR** – commonly associated with lung cancer in Indian and Asian populations
- **KRAS and NRAS** – key markers in colorectal and pancreatic cancers
- **BRAF** – present across multiple tumor types, including melanoma and colorectal cancer

Additionally, the system supports detection of emerging biomarkers such as **MSI (Microsatellite Instability)** and **IDH1/IDH2**, which are increasingly important in determining eligibility for advanced targeted and immunotherapies.

With this addition, Agilus Diagnostics further enhances its integrated oncology diagnostics ecosystem, enabling faster, more efficient biomarker-driven treatment pathways and improved access to advanced cancer care.